ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INSM Insmed Inc

56.89
-0.94 (-1.63%)
Last Updated: 16:25:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
Insmed Inc NASDAQ:INSM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.94 -1.63% 56.89 56.85 56.90 58.10 56.51 57.59 523,034 16:25:06

Insmed To Present at the BofA Securities Health Care Conference 2024

07/05/2024 1:00pm

PR Newswire (US)


Insmed (NASDAQ:INSM)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more Insmed Charts.

BRIDGEWATER, N.J., May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m. PT (5:20 p.m. ET).

The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

(PRNewsfoto/Insmed Incorporated)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-bofa-securities-health-care-conference-2024-302137586.html

SOURCE Insmed Incorporated

Copyright 2024 PR Newswire

1 Year Insmed Chart

1 Year Insmed Chart

1 Month Insmed Chart

1 Month Insmed Chart